The lineage relationship of dendritic cells (DC) with other hematopoietic cell types has been studied extensively, resulting in the identi®cation of different bone marrow (BM) progenitors that give rise to distinct DC types. However, the identity of the different maturation stages of DC precursors in the BM remains unclear. In this study we de®ne the in vivo developmental steps of the myeloid DC lineage in mouse BM. To this end, BM cells were separated according to their expression of CD31 (ER-MP12), Ly-6C (ER-MP20) and ER-MP58 antigens, and stimulated to develop into myeloid DC, using granulocyte macrophage colony stimulating factor as a speci®c growth factor. DC developed from three BM subpopulations: ER-MP12 hi /20 ± (early blast cells), ER-MP12 + / 20 + (myeloid blasts) and ER-MP12 ± /20 hi (monocytes). The kinetic and phenotypic features of DC developing in vitro indicate that the three populations represent successive maturation stages of myeloid DC precursors. Within the earliest ER-MP12 hi /20 ± population, DC precursors exclusively occurred in the myeloid-restricted ER-MP58 hi subset. By using switch cultures, we show that these BM precursor subpopulations, when stimulated to develop into macrophages using macrophage colony stimulating factor, retain the ability to develop into myeloid DC until advanced stages of maturation. Together, these ®ndings support a common ER-MP12/20-de®ned differentiation pathway for both macrophages and myeloid DC throughout their BM development.
Introduction
Dendritic cells (DC) are bone marrow (BM)-derived cells that have the unique capacity to initiate a primary immune response by ef®cient antigen presentation to naive T cells. The DC system is widely distributed throughout the body, and comprises Langerhans cells in epithelial locations, veiled cells in lymph, interdigitating cells in lymphoid organs and interstitial DC in connective tissue of non-lymphoid organs (1) . Many studies in the past few years have addressed the lineage relationships of DC with other hematopoietic lineages. Mainly, DC of two possible origins, lymphoid and myeloid, have been identi®ed in human and mouse. Both types have been shown to originate from the BM from which they can be derived in vitro by stimulation with different growth factors (2± 4). Myeloid DC have been generated in vitro from early common myeloid progenitors in BM and from monocytes in peripheral blood using granulocyte macrophage colony stimulating factor (GM-CSF) as a growth stimulus. In contrast, using Flt-3 ligand (Flt-3L), both myeloid and lymphoid DC can be generated in vitro from BM (5±7). A progenitor population for human lymphoid DC, which also can give rise to lymphoid cells, has been identi®ed in BM and thymus (3) . However, data about this DC lineage in the mouse are inconclusive since the identity of the mature lymphoid DC has been unclear. An earlier study on mouse thymic DC precursors has suggested CD8a as a marker of the lymphoid-related DC lineage (8) . More recent reports, however, show that CD8a is not a reliable marker for lymphoid DC since it can be expressed also on myeloid DC (9) and that CD8a + DC can be derived from myeloid progenitors (10) . A new candidate for the lymphoidrelated DC in the mouse has been proposed (11±13) which shows characteristics equivalent to those of human plasmacytoid DC (PDC).
The developmental plasticity inherent to the DC system has been demonstrated in different studies, showing that both common lymphoid and common myeloid progenitors are able to differentiate into different types of DC (14±16). The studies by Manz et al. and Mebius et al. indicated that both types of progenitors give rise to both CD8a + and CD8a ± DC in vitro and in vivo (14, 15) , while Izon et al. showed a previously unrecognized link between early B cell and DC ontogeny (16) . Furthermore, recent experimental evidence suggests the existence of a common DC precursor in the BM (17) as well as in the peripheral blood (18) for CD8a + , CD8a ± and presumed PDC.
The studies cited above were mainly directed to de®ne the origins of the different DC types and to identify their precursors in the BM. However, the identi®cation of the different developmental stages of DC precursors in the BM still remains unclear. In this study, we have investigated in mouse BM the in vivo differentiation pathway of myeloid DC progenitors identi®ed by differential ER-MP12/CD31 and ER-MP20/Ly-6C expression. In addition, we addressed the developmental relationship of myeloid DC precursors with macrophage precursors.
Methods

Mice
Female C57BL6/J and C57BL6/Ly-5.1-Pep 3b mice between 11 and 13 weeks of age were used in this study. Female C3HeB/ Fej mice were used as a source of allogeneic responder T cells. Animals were speci®c pathogen free, and kept with free access to food and water in the animal care facility at the Erasmus University Rotterdam under the institutional guidelines for usage of experimental animals. mAb and conjugates mAb used for cell sorting,¯ow cytometric analysis, immunocytochemistry and read out of T cell activation in the mixed leukocyte reaction (MLR) were either generated in our laboratory or obtained from BD PharMingen (Alphen aan de Rijn, The Netherlands). These were: biotinylated ER-MP12 (anti-CD31); FITC±ER-MP20 (anti-Ly6C); undiluted hybridoma culture supernatants ER-MP58 (19, 20) , ER-MP21 (anti-CD71/ transferrin R) and M5/114 (anti-MHC class II), obtained in our laboratory; and 53-6.7±FITC (anti-CD8a), RM4-5±PE (anti-CD4) and HL3±phycoerythrin (PE) (anti-CD11c) purchased from BD PharMingen. Biotinylated ER-TR3 (anti-MHC class II) antibody was kindly provided by BMA Biomedicals (Augst, Switzerland). PE±streptavidin, TriColor±streptavidin and PE± goat anti-rat IgG (mouse absorbed) were used as conjugates (Caltag, San Francisco, CA).
Cell suspensions
Single-cell suspensions of BM, isolated from femora and tibiae, were prepared as described previously (20, 21) . Similarly, single-cell suspensions of spleen and lymph nodes were prepared and used for T cell isolation as described (22) . Cultured BM-derived DC were isolated from Te¯on culture bags or from culture plates. Cells were washed in PBS supplemented with 5% FCS (heat inactivated), 60 mg/ml penicillin and 100 mg/ml streptomycin when sterile suspensions were required. Prior to phenotypic analysis, cultured cells were washed with PBS supplemented with 0.5% (v/v) BSA (Organon Teknika, Boxtel, The Netherlands) and 20 mM sodium azide.
Cell sorting and¯ow cytometric analysis
For cell sorting, BM cells were labeled with two (ER-MP12 and ER-MP20) or three (ER-MP12, ER-MP20, and ER-MP58) mAb as described previously (20, 21) . Prior to sorting (FACS Vantage; Becton Dickinson, Amsterdam, The Netherlands), cell suspensions were ®ltered over a 30-mm sieve (Polymon PES; Kabel, Amsterdam, The Netherlands) to avoid clogging of the nozzle. After sorting, the purity of the cell suspensions was checked by re-running sorted samples. Purity was >95%, unless stated otherwise. Suspensions were kept at 4°C throughout the staining and sorting procedure. Sorted cells were counted in a Bu È rker hemocytometer.
For¯ow cytometric analysis, samples of cultured cells (b2 Q 10 4 cells) were aliquoted into 96-microwell plates (round bottom; Nunc, Roskilde, Denmark) and labeled with antibodies as described before (21) . Samples were analyzed on a FACSCalibur¯ow cytometer using CellQuest analysis software (Becton Dickinson).
Immunocytochemistry on poly-L-lysine-coated slides
For immunocytochemical analysis, aliquots of cultured cells were placed at 37°C, 7% CO 2 in complete medium for 1 h to adhere to poly-L-lysine-coated microwell slides (Nutacon, Schiphol-Oost, The Netherlands). Next, cell preparations were gently washed once with PBS (37°C), ®xed in 1% paraformaldehyde in PBS for 10 min at room temperature, and washed with PBS and with PBS supplemented with 0.5% BSA. Cells were incubated with primary mAb, followed by rabbit anti-rat IgG conjugated to horseradish peroxidase (HRP; Jackson ImmunoResearch, West Grove, PA) (both incubations 30 min at room temperature). Diaminobenzidine (DAB; Sigma, St Louis, MO) was used as substrate. Between incubations, cell preparations were washed in PBS supplemented with 0.5% (v/v) Tween 20. After the DAB reaction was completed (3±5 min at room temperature), the cell preparations were dehydrated and coverslipped using Entallan (Merck, Darmstadt, Germany). Antibody reactivity was determined under a light microscope. Culture supernatant of the Y3 myeloma followed by the second stage antibody was used as negative control.
Growth factors
Conditioned medium of LADMAC cells was used as a source of mouse macrophage colony stimulating factor (M-CSF) (23) . Conditioned medium was prepared as described elsewhere (19) . Recombinant mouse GM-CSF (rGM-CSF) was purchased from Biosource International (Camarillo, CA).
rGM-CSF-and M-CSF-stimulated BM cultures
DC were generated by culturing total BM or isolated subsets in Te¯on culture bags (24) or 24 well plates (Nunc) in RPMI-1640 (no HEPES; Biowhittaker, Verviers, Belgium) supplemented with 10% FCS (heat inactivated; 0.2 mm ®ltered), 60 mg/ml penicillin, 100 mg/ml streptomycin and 20 ng/ml rGM-CSF. Cells were cultured at 37°C, 7% CO 2 for various periods of time, as indicated, for up to 14 days. Differentiation of isolated BM subsets, to macrophages, was induced by culturing in Te¯on culture bags (24) in IMDM (with glutamax I; Gibco, Invitrogen BV, Breda, The Netherlands) supplemented with 20% FCS (heat inactivated; 0.2 mm ®ltered), 15% LADMACconditioned medium as a source of M-CSF, 100 mM 2-mercaptoethanol, 60 mg/ml penicillin and 100 mg/ml streptomycin. Cells were cultured for 4 or 5 days at 37°C, 7% CO 2 as indicated.
MLR
In vitro generated DC (stimulator cells) and T cells (responder cells) isolated from the spleen and lymph nodes were resuspended in RPMI 1640 supplemented with 25 mM HEPES, 10% FCS (heat inactivated; 0.2 mm ®ltered), 60 mg/ ml penicillin, 100 mg/ml streptomycin, 20 mg/l sodium pyruvate and 50 mM 2-mercaptoethanol (further referred to as MLR medium). T cells were resuspended at a concentration of 2 Q 10 6 /ml and the concentration of DC varied depending on the desired ratio of DC:T cells. The cells (100 ml of each cell suspension) were incubated in round-bottom 96-well plates for 4 days at 37°C, 7% CO 2 . DC and T cells, incubated separately in MLR medium, were used as negative controls. Mitogenic stimulation of T cells by concanavalin A (®nal concentration 1.25 mg/ml) (Sigma) was used as a positive control.
After 4 days of co-culture, cells were harvested and analyzed by¯ow cytometry. Triple labeling of cells with anti-CD4, anti-CD8 and ER-MP21 antibodies was performed, and 15,000 events within the living gate was acquired. Analysis was performed using CellQuest analysis software. The percentage of ER-MP21 (CD71/transferrin R) + cells, as a measure of proliferating cells, was determined within the CD4 + and CD8 + population. This method of analysis provides comparable results to those obtained with the [ 3 H]thymidine incorporation method (unpublished results) and in addition allows us to analyze, in more detail, the characteristics of the responding T cell population
Results
Distinct DC precursors in the BM can be identi®ed by ER-MP12/20 labeling
Based on ER-MP12/CD31 and ER-MP20/Ly-6C expression, we can fractionate BM into six separate, morphologically and phenotypically distinct subsets ( Fig. 1) as we showed previously (25, 26) . We also demonstrated that in this way the different hematopoietic lineages (lymphoid, erythroid, granulocytic and monocytic) and three different stages of macrophage precursors could be distinguished (21, 26) . To examine in which of the cell populations DC precursors were present, BM subsets were sorted and cultured with GM-CSF. At day 10 of culture, the development of DC was evaluated by examining the cultures under an inverted light microscope (Table 1) . DC were clearly visible in cultures derived from ER-MP12 hi 20 ± , ER-MP12 + 20 + and ER-MP12 ± 20 hi subsets. No DC or other cell (21, 26) . The presence of DC in cultures was also examined by assessing MHC class II expression in immunocytochemistry (Fig. 2) . DC derived from different precursor populations showed the same typical DC morphology with MHC class II molecules present preferentially on the cell surface. However, the frequency of MHC class II hi DC at day 6 (Table 1) in the ER-MP12 hi 20 ± culture was lower than that in the ER-MP12 + 20 + and ER-MP12 ± 20 hi cultures (an average of 6 versus 33 and 25% respectively), suggesting that precursors from the ER-MP12 hi 20 ± population needed more time to develop into DC. This was in agreement with the results from visual examination of the cultures. By day 10, the frequency of DC had increased in the cultures derived from the ER-MP12 hi 20 ± subset (on average 12%), but was still lower than that in the ER-MP12 + 20 + (16%) and ER-MP12 ± 20 hi (on average 37%) subsets. In conclusion, on the basis of differential ER-MP12 and ER-MP20 expression, we can distinguish three subsets in mouse BM from which DC can be derived with GM-CSF.
DC derived from different ER-MP12/20 populations develop into fully mature cells
Immature and mature DC differ in the level of MHC class II molecule expression on their surface. To determine the maturation state of DC derived with GM-CSF from different BM subpopulations, we double-stained cells at the end of culture with CD11c and anti-MHC class II antibodies. On the gated CD11c+ population, we measured the expression of MHC class II molecules (Fig. 3A) (Fig. 3B) . All cultures contained also some CD11c ± MHC class II ± cells (not shown), which are mainly granulocytes also developing in vitro with GM-CSF.
To investigate the functionality of DC derived from different precursor subpopulations, we assessed their antigen-presenting capacity by co-culturing GM-CSF derived cells with puri®ed T cells (Fig. 3C) . DC derived from all three BM subpopulations were good activators of T cells. The MLR stimulatory capacity was enhanced after LPS stimulation, particularly in the culture derived from the ER-MP12 hi 20 ± subpopulation when tested at lower DC:T cell ratios.
Three ER-MP12/20-de®ned subpopulations represent successive maturation stages of DC precursors in the BM Morphological and functional analysis of DC cultures showed that different BM subpopulations develop with different kinetics into similar DC, which suggests that precursors in these populations might be in a different maturation stage at the time of isolation. To investigate this, we sorted the ER-MP12 hi 20 ± , ER-MP12 + 20 + and ER-MP12 ± 20 hi subpopulations from the BM, stimulated them with GM-CSF in vitro, and analyzed the expression of ER-MP12 and ER-MP20 by cultured cells at various time points (Fig. 4) .
At day 2 of culture, cells from the ER-MP12 hi 20 ± subpopulation had up-regulated ER-MP20 on their surface and about a half of them were double positive for both markers. By day 5 all cells derived from this population were ER-MP20 + while most of them showed no ER-MP12 expression anymore. By day 8, the culture contained ER-MP12/20 double-negative cells and those that expressed medium levels of ER-MP20. The ER-MP12 + 20 + population followed a similar pathway of development. At day 2, most of the cells had down-regulated ER-MP12 expression and were ER-MP12 ± 20 + . At day 5 of culture, some cells also down-regulated ER-MP20 and were double negative. By day 8 almost all cells had lost both markers on their surface and were ER-MP12 ± 20 ± . Finally, the ER-MP12 ± 20 hiderived cells also down-regulated ER-MP20 on majority of the cells by day 5 of culture. By day 8 most of the cells in this culture had died (they probably were fully differentiated already before day 8) so no phenotypical analysis could be performed at this time point. Importantly, in all investigated cultures cells successively pass through the ER-MP12 + 20 + and ER-MP12 ± 20 hi stages and ®nally become ER-MP12 ± 20 ± .
In the same cultures we followed the development of DC by using the DC marker CD11c. A common pattern of in vitro DC development was observed in cultures from all three fractions: ®rst CD11c expression was induced followed by a prompt down-regulation of ER-MP20 (Fig. 5) . CD11c + cells were present already at day 2 in the culture derived from the ER-MP12 ± 20 hi subpopulation. CD11c + cells were also present at day 2 in cultures derived from the ER-MP12 + 20 + subpopulation, but at much lower frequency. The percentage of CD11c + cells was increased in both cultures at day 5 and continued to rise in cultures derived from the ER-MP12 + 20 + subpopulation to reach 91% at day 8 of culture. In contrast, in cultures derived from the ER-MP12 hi 20 ± precursors, CD11c + cells were present only from day 5 (10%) and reached 45% at day 8 of culture, implying that these precursors are indeed the earliest precursors able to differentiate into DC when stimulated with GM-CSF.
The maturation sequence of BM DC precursors, indicated by these phenotypic studies, is consistent with the decreasing proliferative capacity of the cells with increasing maturity. GM-CSF-stimulated culture of the distinct subsets in semi-solid medium demonstrated that the ER-MP12 hi 20 ± subset generated predominantly large colonies (>50 cells), the ER-MP12 + 20 + subset predominantly clusters (<50 cells) and some smaller colonies, while the ER-MP12 ± 20 hi subset gave rise primarily to small clusters. Liquid culture recoveries were in line with these ®ndings. In a representative experiment, 1 Q 10 5 cells from the ER-MP12 hi 20 ± population produced 4 Q 10 6 cells after 7 days of culture, thus multiplying their starting number 40 times. From 4 Q 10 5 ER-MP12 + 20 + cells, 3.6 Q 10 6 progeny cells (9-fold) were generated, while 4 Q 10 5 ER-MP12 ± 20 hi cells gave rise to only 2.8 Q 10 5 cells after culture (0.7-fold).
The earliest ER-MP12 hi 20 ± DC precursors have the phenotype of myeloid-committed cells
Previously, we showed that the same ER-MP12/20-de®ned subpopulations in the BM contain macrophage precursors as we found now for DC precursors (21) . In addition, we also showed that within the ER-MP12 hi 20 ± subpopulation, early myeloid-committed cells could be puri®ed from the other hematopoietic differentiation capacities on the basis of differential expression of a third marker, ER-MP58 (20) . Since we found that DC could also be generated from the ER-MP12 hi 20 ± BM subset, we asked whether the earliest DC precursors also have a myeloid-committed phenotype by examining their ER-MP58 expression. For this purpose, ER-MP12 hi 20 ± BM cells were fractionated according to their level of ER-MP58 expression (Fig. 6) and cultured in the presence of GM-CSF. Cultures were examined microscopically for the presence of DC at different time points. Starting from day 7 ( Table 2) , morphologically mature DC could only be detected in cultures of the ER-MP58 hi subset within the ER-MP12 hi 20 ± population. This onset of DC appearing in culture was similar to what was observed when the total ER-MP12 hi 20 ± subset was cultured (see above). No DC-like cells could be grown from the ER-MP58 med and ER-MP58 ±/lo subsets under these culture conditions. Together, these data show that, like macrophage precursors, GM-CSF-responsive DC precursors present in the ER-MP12 hi 20 ± BM subset are characterized by a high level of ER-MP58 expression and thus have a myeloid-committed phenotype.
BM progenitors maturing along the macrophage lineage in vitro maintain the capacity to generate DC To approach the question whether macrophages and DC share progenitors throughout their BM development, we cultured BM subsets sequentially with M-CSF (`primary culture') and GM-CSF (`secondary culture'). ER-MP12 hi 20 ± 58 hi (early myeloid precursors) and ER-MP12 + 20 + (myeloid blasts) were induced ®rst to develop along the macrophage lineage in vitro (21). M-CSF was then replaced by GM-CSF and the potential of macrophage precursors to form DC was measured.
After 4 days in M-CSF-stimulated culture of the ER-MP12 hi 20 ± 58 hi subset,~90% of the cultured cells expressed the ER-MP20 antigen at a high level (Fig. 7A) , representing BM monocytes as previously shown (21) . Changing the growth stimulus to GM-CSF at this point resulted in the appearance of DC only 1 day later as determined by morphological inspection. The more mature ER-MP12 + 20 + subset developed further along the macrophage pathway in vitro, since after 5 days of M-CSF-stimulated culture approximately half of the cells still expressed the ER-MP20 antigen, whereas the other cells in the culture had lost their ER-MP20 expression (Fig. 7B) . When these cells were further stimulated by GM-CSF, similarly to ER-MP12 hi 20 ± 58 hi -derived cultures, DC were visible after only 1 day of secondary culture and in increased numbers after 3 days of culture. Apart from DC, macrophages (ER-MP20 ± ) also developed in cultures from both precursor fractions as indicated by the presence of cells with (i) high forward and perpendicular light scatter (data not shown), indicative of a complex cell type like the mature macrophage with its numerous vacuoles, etc., and (ii) a high auto¯uorescence level, also characteristic of mature macrophages. After 9 days of GM-CSF-stimulated secondary culture, 28 and 71% DC developed from ER-MP12 hi 20 ± 58 hi and ER-MP12 + 20 + derived cultures respectively. These cells expressed MHC class II molecules at a high level and had typical DC morphology, as determined in immunocytochemistry (Fig. 7C and D) . Thus, myeloid precursors from the BM developing for 4 or 5 days along the macrophage lineage in M-CSF-stimulated culture still have the potential to generate DC.
Discussion
In the past few years a signi®cant amount of data has been generated about different DC types and their relationship to other hematopoietic lineages. Recently, it has been shown that both common myeloid and common lymphoid precursors can give rise to different DC types both in vitro and in vivo (14±16). Mature myeloid and lymphoid DC have been identi®ed phenotypically in human and also in mouse (3, 4) . However, the exact maturation pathways of either of the types have remained unclear.
In this study we have examined the different stages of BM DC precursor development in vivo, as de®ned by the expression of ER-MP12/CD31, ER-MP20/Ly-6C and ER-MP58 antigens. DC are derived in vitro with GM-CSF only from the ER-MP12 hi 20 ± (early blasts), ER-MP12 + 20 + (myeloid blasts) and ER-MP12 ± 20 hi (BM monocytes) (21) subpopulations, while no cell growth could be detected from the other three sorted populations, ER-MP12 med 20 ± , ER-MP12 ± 20 ± and ER-MP12 ± 20 med . These populations represent subsets containing morphologically identi®able precursors and mature cells of the other hematopoietic lineages (lymphoid, erythroid and granulocytic respectively). Our results show that GM-CSFresponsive DC precursors reside in the same ER-MP12/20-de®ned BM subsets as M-CSF-responsive macrophage precursors (19±21).
Earlier reports show that mature DC develop from the BM within 8 days in GM-CSF-stimulated culture (27) . In agreement with this we observe that the majority of DC derived from any of the BM subpopulations express signi®cant amounts of MHC class II molecules, which, together with their good potential to stimulate allogeneic naive T cells in vitro, indicates that mature DC develop in these cultures. However, in cultures derived from the ER-MP12 hi 20 ± cells, immature DC, expressing medium levels of MHC class II, were also present in signi®cant numbers after 7 days of culture. These cells mature upon LPS stimulation, suggesting that they need an extended period of time to develop into mature DC since they develop from early precursors. This delay in reaching a mature state is in agreement with the observation that during the in vitro development, a difference in time of appearance of CD11c + cells exists in cultures grown from the ER-MP12 hi 20 ± versus the ER-MP12 + 20 + and ER-MP12 ± 20 hi BM subsets (day 5 versus 2 respectively). This further implies that ER-MP12 hi 20 ± DC precursors are less mature than the other two subsets, and need more time to develop into DC than ER-MP12 + 20 + and ER-MP12 ± 20 hi cells. In addition, the percentage of CD11c + DC derived from the GM-CSF-stimulated ER-MP12 + 20 + cells is 2-fold higher than that found with the ER-MP12 hi 20 ± BM subset as a starting population (90 versus 45%). Probably the higher proliferative capacity of the ER-MP12 hi 20 ± population contributes to the observed difference in maturation kinetics. Both the size and extent of colony/cluster formation and culture recoveries indicate that ER-MP12 hi 20 ± cells have the highest potential to proliferate, which then decreases to be the lowest among ER-MP12 ± 20 hi cells. The high recoveries obtained from the ER-MP12 hi 20 ± and ER-MP12 + 20 + fractions make it highly unlikely that contaminating populations (<5%) in the sorted fractions account for the observed results. Together, these ®ndings reinforce the notion that ER-MP12 hi 20 ± , ER-MP12 + 20 + and ER-MP12 ± 20 hi populations represent different stages of DC development, since they show a reciprocal relationship between the ability to proliferate and the ability to develop into mature DC in a short period of time.
The successive expression of ER-MP12 and ER-MP20 antigens during the in vitro culture with GM-CSF strongly suggests that the three DC precursor populations, which we de®ned in the BM, differentiate along the pathway with the order ER-MP12 hi 20 ± ® ER-MP12 + 20 + ® ER-MP12 ± 20 hi . Furthermore, this same sequence was previously shown for the macrophage precursors (21) suggesting that GM-CSFresponsive myeloid DC and macrophage precursors follow a similar ER-MP12/20-de®ned developmental pathway.
The population that contains the earliest DC precursors in the BM, ER-MP12 hi 20 ± , can be further divided into three subpopulations based on the expression of the early myeloid marker ER-MP58 (20) . Of these three subsets, only ER-MP12 hi 20 ± 58 hi BM cells are able to differentiate into DC in rGM-CSF-stimulated cultures. Since high level expression of ER-MP58 within the ER-MP12 hi 20 ± BM population has been shown to mark the earliest myeloid committed precursors, able to give rise to macrophages with M-CSF (20), we conclude that macrophages and myeloid DC most probably originate from the same precursors in the BM. Recently, Akashi et al. have described the existence of a common myeloid progenitor in mouse BM that gives rise to all myeloid lineages (10) . The comparison of its colony forming ability and further characteristics with those of the ER-MP12 hi 20 ± 58 hi population strongly suggests that the latter represents a similar, if not identical, multipotent myeloid precursor population.
In a recently published paper (7), Gilliet et al. show that the mouse PDC (CD11c + CD11b ± B220 + ) can be generated in vitro from the total BM, when Flt-3L is used as the growth factor. They also show that addition of GM-CSF to the culture medium completely blocks generation of PDC and increases myeloid DC development. Since we used GM-CSF alone, this is in agreement with the observation that in our cultures, no plasmacytoid, but only myeloid DC, were generated as all cells in the culture expressed high levels of CD11b (data not shown). An interesting question arises regarding the potential of our three populations to generate PDC with Flt-3L. For the BM monocyte population (ER-MP12 ± 20 hi ) we regard it unlikely that they may give rise to lymphoid-related PDC, as we have shown previously that BM monocytes are all CD11b + and thus myeloid cells (21) , Further, it has been reported that the CD31 + /Ly-6C + (i.e. our ER-MP12 + 20 + ) population contains precursor cells capable of differentiating into different cell types: CD8a + DC, CD8a ± DC, PDC and macrophages, depending on the experimental conditions (17) . Our current results support the concept that developing myeloid DC, which might eventually express CD8a, and macrophages progress through the same precursor stages in the BM including the CD31 + /Ly-6C + stage. However, as we have shown earlier, the CD31 + Ly-6C + population in BM is phenotypically heterogeneous (21) and might contain cells with different developmental capabilities; clonal assays are essential to prove whether PDC and myeloid DC derive from single precursors. Finally, we de®ne the DC precursor, at the stage prior to the one previously reported, which is capable of differentiating in both myeloid DC and macrophages (CD31 hi / Ly-6C ± ). As mentioned above, since GM-CSF directs cell development speci®cally to myeloid lineage, it is unclear from our data whether PDC might originate from the same population.
Taken together, in this report, we de®ne different stages of GM-CSF-responsive DC precursors present in the BM and show their in vivo developmental pathway. Furthermore, we show that, throughout their BM development, myeloid DC precursors progress through the same stages as macrophages. Even when cells are induced in vitro with M-CSF to follow the macrophage developmental pathway, they can still be redirected to develop into DC when M-CSF is replaced with GM-CSF. This is in line with our hypothesis that over a prolonged stretch of development, progenitors of the mononuclear phagocyte system may either develop into macrophages or DC, depending on local conditions. However, additional clonal experiments are required to con®rm this hypothesis. Finally, we feel that the ER-MP12/20/58 identi®cation of distinct BM subsets provides a powerful means to study the developmental pathway of lymphoidrelated PDC as opposed to the presently studied myeloid DC.
